IMPRIVATA
15.10.2014 09:01:36 CEST | Business Wire | Pressemeddelelse
VMworld® (booth E160) -- Within the next 24 months, 74 percent of organisations in Europe adopting virtual desktop infrastructure (VDI) plan to implement single sign-on (SSO), according to new research from Imprivata ®, a leading provider of authentication, access management solutions for the healthcare industry. The Imprivata 2014 Desktop Virtualisation Trends in Europe report also finds that overall adoption of VDI is expected to reach 65 percent within the next 24 months, and in healthcare, 71 percent of organisations expect to be using VDI within the next two years.
“Our virtual desktop infrastructure enables our clinical staff to add roaming desktops and mobility into their work routines, and allowed us to replace about 1,000 desktop PCs with thin clients,” said Justin Beardsmore, Infrastructure Manager, St. George’s Healthcare NHS Trust (London). “By adding SSO and strong authentication though Imprivata OneSign , our providers are collectively saving more than 50 hours every week. The combination of VDI, thin clients, mobile devices and Imprivata OneSign has kick-started St. George’s journey into the mobile health era.”
Key findings from the Imprivata 2014 Desktop Virtualisation Trends in Europe report include:
- Adoption rates of VDI increased from 41 percent in 2013 to 49 percent in 2014. This trend is expected to continue, with VDI adoption forecasted to reach 65 percent within 24 months. The use of VDI in healthcare is outpacing other industries, with adoption levels expected to reach 71 percent over the next 24 months.
- Today, 46 percent of organisations that use VDI also use SSO, which is an increase of 18 percent from 2013. This is expected to continue to increase, with 74 percent of organisations indicating they will implement SSO with their VDI environments over the next 24 months.
- Adoption of zero clients to support VDI is expected to increase 45 percent over the next 24 months, while adoption of thin clients is expected to increase eight percent over that time frame. The use of tablets and smartphones for VDI is also expected to increase sharply, particularly in healthcare.
“The results of the Imprivata 2014 Desktop Virtualisation Trends in Europe report mirror what we continue to hear from our global customers—implementing authentication management solutions to delivering fast, secure access to mission-critical applications and information is integral to unlocking the full potential of desktop virtualisation,” said Clay Ritchey, chief marketing officer at Imprivata. “The combination of these technologies is especially beneficial in healthcare, where providing instant access to clinical applications and patient data at the point of care can significantly improve efficiency while also meeting security and compliance requirements.”
To download the complete 2014 Imprivata Desktop Virtualisation Trends in Europe report, click here .
Methodology
A total of 101 respondents from across the healthcare, financial services, government and other industries in Europe were surveyed to understand their organisation’s adoption rates of desktop virtualisation. Responses were collected from organisations of varying size based on number of employees for non-healthcare respondents and number of beds for healthcare respondents.
About Imprivata
Imprivata (NYSE: IMPR) is a leading provider of authentication and access management solutions for the healthcare industry. Imprivata’s single sign-on, authentication management and secure communications solutions enable fast, secure and more efficient access to healthcare information technology systems to address multiple security challenges and improve provider productivity for better focus on patient care. For more information, please visit www.imprivata.com .
This press release may include forward-looking statements regarding anticipated objectives, growth and/or expected product and service developments or enhancements. Such forward-looking statements may be identified by the use of the following words (among others): "believes," "expected," "may," "will," "plan," “growing”, "should", “expected”, "anticipates" or comparable words and their negatives. These forward-looking statements are not guarantees but are subject to risks and uncertainties that could cause actual results to differ materially from the expectations contained in these statements. For a discussion of such risks and uncertainties, see "Risk Factors" in Imprivata’s filings with the Securities and Exchange Commission, including its most recent report on Form 10-Q. Imprivata assumes no obligation to update any forward-looking statements contained in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.
Contact:
PR Contact:
Imprivata
Dan Borgasano, +1-781-430-2812
dborgasano@imprivata.com
or
IR
Contact
:
Westwicke Partners
Bob East / Asher Dewhurst,
443-213-0503
bob.east@westwicke.com
imprivata@westwicke.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
